Raymond James Downgrades Fusion Pharmaceuticals to Market Perform From Strong Buy, Raises Price Target to $21 From $16
Raymond James Downgrades Fusion Pharmaceuticals to Market Perform From Strong Buy, Raises Price Target to $21 From $16
雷蒙德·詹姆斯將Fusion Pharmicals的評級從強勢買入下調至市場表現，將目標股價從16美元上調至21美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊